A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy

What is the purpose of this trial?

The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.



Fox Chase Cancer Center

Dates: 05/23/2017 - 12/01/2017

Last Updated: 06/11/2017

Study HIC#: 1603017389

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367
matthew.piscatelli@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Brian M. Shuch

Principal Investigator

Sub-Investigators